首页> 美国卫生研究院文献>ESMO Open >First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

【2h】

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

机译：即使在先进的Al淀粉样源病中一线达拉姆姆人也显示出高疗效和耐受性：真实的体验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response rates in relapsed immunoglobulin light-chain (AL) amyloidosis.

机译：Daratumumab是第一种单克隆CD38抗体，其具有批准用于治疗多发性骨髓瘤的单孕活性。此外，达拉姆巴亚可展示了复发的免疫球蛋白轻链（Al）淀粉样蛋白症的高响应速率。

著录项

期刊名称 ESMO Open
作者
G. Jeryczynski; M. Antlanger; F. Duca; C. Binder-Rodriguez; T. Reiter; I. Simonitsch-Klupp; D. Bonderman; R. Kain; M.-T. Krauth; H. Agis;
展开▼
作者单位

展开▼
年(卷),期 2021(6),2
年度 2021
页码 100065
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
amyloidosis; AL; light chain; immunotherapy; daratumumab;

机译：淀粉样蛋白化;al;轻链;免疫疗法;甘肃;

相似文献

外文文献
专利

1. Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review [J] . Rahman Muhammad Aadil, Khan Ali Younas, Ijaz Awais, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：达拉姆渣在重预处理的Al淀粉样症中的功效和耐受性：系统评价
2. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience [J] . Hanbo Zhang, Curtis Kellett, Pascal Lambert, Clinical colorectal cancer . 2018,第3期

机译：二线Nab-PACLITAXEL和吉西他滨术失败后的高级胰腺癌失败后的疗效和耐受性：单机制经验
3. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience [J] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, OncoTargets and therapy . 2016,第2期

机译：吉非替尼联合培美曲塞维持一线铂类双联化疗在晚期肺腺癌中的疗效和耐受性比较：单中心经验
4. A SINGLE-CENTER EXPERIENCE USING CHEMOTHERAPY WITH MELPHALAN-DEXAMETHASONE (M-DEX) IN PATIENTS WITH AL AMYLOIDOSIS AND ADVANCED ORGAN INVOLVEMENT NOT ELIGIBLE FOR HIGH-DOSE MELPHALAN THERAPY (HDM) [C] . U. Hegenbart, T. Bochtler, J.B. Dengler, International Symposium on Amyloidosis . 2008

机译：使用化学疗法的单中心经验与Melphalan-Dexamethasone（M-DEX）的Al淀粉样蛋白病和先进器官参与没有资格获得高剂量Melphalan治疗（HDM）
5. Efficacy, Tolerability and Safety of Operating Room Microlaryngoscopy Versus Office-Based Potassium Titanyl Phosphate (KTP) Laser Treatment of Benign Vocal Fold Lesions: A Longitudinal Prospective Evaluation of Multidimensional Voice Outcomes [D] . Chadwick, Keith Alan. 2020

机译：手术室微淋镜检查的功效，耐受性和安全性与良性声带病变的基于办事处的磷酸钾（KTP）激光治疗：多维语音结果的纵向前瞻性评估
6. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience [O] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, 2016

机译：吉非替尼联合培美曲塞维持一线铂类双联化疗在晚期肺腺癌中的疗效和耐受性比较：单中心经验
7. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience [O] . G. Jeryczynski, M. Antlanger, F. Duca, 2021

机译：即使在先进的Al淀粉样源病中，一线达拉姆姆人也显示出高疗效和耐受性：真实的体验

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

摘要

著录项

相似文献

相关主题

期刊订阅